The vaccine reduced risk of death for certain acute myeloid leukemia patients, according to drugmaker
Analyst rates Sellas Life Sciences a Sell: its roughly $4 billion valuation outstrips GPS's roughly $826 million risk-adjusted U.S.
It wasn't Merck and Moderna this time. A third player has entered the chat.
- REGAL trial met its primary endpoint with GPS demonstrating statistically significant and clinically meaningful reduction in risk of death by 41% with median overall survival of 24.0 months versus 14.7 months for best available treatment, and a hazard ratio of 0.59 (p=0.035) - - Company plans to meet with the U.S. Food and Drug Administration (FDA) while advancing preparations for a Biologics License Application (BLA) submission for GPS - - SELLAS to host webcast today, November 17, 2026, at 7
SELLAS Life Sciences (SLS) stock fell as the company hits a final analysis milestone in its Phase 3 REGAL trial, setting up a topline data readout. Read more here.
Sellas Life Sciences remains a 'Strong Sell,' as the REGAL trial delay signals increased risk of failure and diminished probability of success. Learn more about SLS stock here.
Sellas Life Sciences is a late-stage biotech with no product sales, hinging on its Phase 3 REGAL trial for GPS in AML. Click to know why I rate SLS stock a Hold.
Shares of Sellas Life Sciences Group Inc. (NASDAQ:SLS) nosedived by 16.6 percent in the third quarter of the year—from $14.76 on June 30 to $12.31 on Wednesday—as sentiment was dragged down by the delays and uncertainties surrounding the clinical results of its treatment candidate for acute myeloid leukemia (AML). In Wednesday’s trading alone, the stock […]
SELLAS Life Sciences Group has delivered a very large 3 year return, which puts a spotlight on whether the current share price around US$11.51 still lines up with what its balance sheet is worth on paper. With that kind of move behind it and new cancer therapy data in play, the question now is how much value investors are effectively placing on SELLAS' book value. Over the past 3 years, the stock has gained roughly 7x. This makes the relationship between its recent share price performance...
SLS009 increased apoptosis more than six-fold versus daraxonrasib in a MYC-amplified, daraxonrasib-resistant patient-derived pancreatic cancer organoid model - Combination of SLS009 and daraxonrasib further increased apoptosis to 36.5% and necrosis to 30.6%, supporting evaluation of CDK9 inhibition as a potential strategy to enhance RAS-directed therapy -SLS009 combined with BET inhibition demonstrated synergistic activity and sustained suppression of MYC, providing additional evidence of SLS009
Sellas said earlier laboratory work showed activity against pancreatic cancer cells resistant to RAS-targeting drugs.
SELLAS Life Sciences is rated Hold, with a $9.25 price target, as the current valuation reflects REGAL trial success probability. Read more on SLS stock here.
SELLAS Life Sciences Group (NasdaqCM:SLS) will present new preclinical data on SLS009 in pancreatic ductal adenocarcinoma at the 2026 AACR Conference. Three abstracts on SLS009 have been accepted, focusing on its mechanism of action and activity in KRAS mutant pancreatic cancer models. The research is being carried out with a respected academic institution and adds detail on SLS009 within SELLAS Life Sciences Group's preclinical pipeline. Interest in SELLAS Life Sciences Group reflects a...
- Three posters to highlight preclinical activity of SLS009 (tambiciclib) across patient-derived KRAS mutant organoid models of pancreatic cancer – - Studies conducted in collaboration with the University of Wisconsin School of Medicine and Public Health - NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer
The most-talked-about stocks in the Reddit subforum Wallstreetbets were mixed hours before Monday's
Editor’s Note: The story has been refreshed with the latest market price action and a revised headline. Short seller BMF Capital disclosed a short position in SELLAS Life Sciences Group Inc., arguing the market has “dangerously overvalued” the biotech company...
Sellas Life Sciences (NASDAQ:SLS) saw its share price decline by 13.15 percent on Friday to close at $13.21 apiece, as investors turned increasingly concerned about the company’s silence about its treatment candidate for acute myeloid leukemia (AML). The drop was triggered by a report from a Germany-based news site that the company has already hit […]
Virginia Retirement System disclosed SLS and IBRX stakes worth nearly $909,000 combined.
Sellas shares reached a swing high of $15.88 in late June before tumbling 42% to a July low of $9.19.
This is the newest page. Registered accounts read further back.